iProcess Global Research Inc. is a leading global provider of biospecimens and laboratory services, with over 20 years of experience and a global network of over 1500 sites. | iProcess Global Research Inc. is a leading global provider of high-quality human biospecimens and comprehensive laboratory services, dedicated to empowering scientific research and accelerating medical breakthroughs. With more than 22 years of experience supporting the life sciences, pharmaceutical, biotechnology, and diagnostic industries, iProcess connects researchers to ethically sourced, clinically annotated human biospecimens through a robust network of 1,500+ pre-qualified clinical sites across over 30+ countries. Built on a foundation of strict regulatory compliance and quality excellence—including ISO 20387 and CAP/CLIA-aligned workflows—iProcess offers end-to-end solutions ranging from customized specimen collection and validated cold-chain logistics to advanced, AI-enhanced laboratory analysis and project management support. iProcess’s global biorepository and laboratory ecosystem provides seamless access to a broad range of human sample types and disease cohorts, enabling organizations to navigate complex research requirements with reliability, flexibility, and scientific integrity. Whether supporting clinical trial biospecimen procurement or delivering integrated lab services, iProcess is committed to advancing research and delivering data researchers can trust. As part of its continued expansion in laboratory services, iProcess is launching AxisOne.ai in February 2026—an AI-powered global R&D platform designed to connect organizations with world-class laboratories and research capabilities worldwide. AxisOne leverages artificial intelligence and deep analytics to accelerate feasibility, optimize lab selection, and streamline execution for specialized testing needs by bringing hundreds of labs and research sites onto a single intelligent platform.
Harvest Integrated Research Organization (HiRO)
HiRO is a modern global CRO delivering full-service clinical trial support across ANZ (for over 25 years), APAC, US, and Europe. We combine global infrastructure with genuine local expertise, offering sponsors the agility and personalization that larger organizations can’t match, without sacrificing rigor or reach. From regulatory strategy, clinical operation support and management, site identification and management, biometrics, pharmacovigilance and medical monitoring, HiRO accelerates the path from discovery to patients. Highlights ⦁ Modern local CRO operating across ANZ, APAC, US, and Europe ⦁ Full-service: clinical design, regulatory, biometrics, safety, and monitoring ⦁ Global expertise paired with hands-on regional insight ⦁ Agile operations built for faster, cleaner clinical data ⦁ True partnership model, embedded in your team from day one | Harvest Integrated Research Organization (HiRO) is a globally oriented, innovative clinical research organization (CRO). With global operations and integrated capabilities, HiRO provides a full range of cross-border solutions and services to its clients, including early pre-clinical strategic planning, clinical trial design, regulatory affairs, pharmacovigilance, statistics, data management, end-to-end project management, and clinical and medical monitoring services. As an emerging global CRO, HiRO strives to become a market-leading, integrated global clinical research organization that works collaboratively with biotech and pharmaceutical companies to bring new products from the laboratory to the market, providing more effective solutions for patients worldwide.
EPS Group
From our beginnings in 1991 as a systems company built on medical statistics, the EPS Group has responded to customer needs amid structural changes in the market and increasingly rigorous and complex drug development. EPS has evolved as a CRO (Contract Research Organization) and expanded our offerings to include SMO (Site Management Organization) and CSO (Contract Sales Organization) services, thereby becoming a comprehensive provider of various support services for the healthcare industry. CRO： In response to requests from pharmaceutical, medical device and regenerative medicine companies, medical institutions, governmental agencies, and others, the EPS CRO Group provides One-Stop Solutions to support the development of pharmaceuticals, medical devices, foods, and cosmetics. SMO： The EPS SMO Group enhances clinical trials by collaboration with medical institutions across Japan, leveraging digital technology to improve efficiency, including the promotion of Decentralized Clinical Trials (DCTs) and the development of remote systems for clinical trial document management. CSO： The EPS CSO provides targeted support to pharmaceutical and medical device manufacturers after product approval. We provide contact center operations, and a range of services from pre-approval to post-marketing stages, employing a skilled workforce to effectively fulfill customer needs. | EPS Holdings, Inc., a Japanese headquartered company, is a comprehensive provider of clinical trial and research outsourced services. EPS Group, with over 7,800 staff, provides quality support to pharmaceutical, biotech, regenerative medicine, and medical device companies. Core businesses are CRO, SMO, Contract Sales Support, and China product development and distribution. EPS operates in Japan, China, South Korea, and Taiwan and, through a partner, supports studies in other Asia-Pacific countries. Looking towards the future, we will strengthen our forward-looking spirit expressed as an “Ever Progressing System.” | The EPS Group was founded in 1991 as a pioneer in the domestic Contract Research Organization (CRO) industry. Since then, we have expanded our diverse services, including Site Management Organization (SMO) and Contract Sales Organization (CSO), with a primary focus on CRO. We provide end-to-end support solutions from the development of pharmaceuticals, medical devices, and regenerative medicine products to post-marketing surveillance. Building on the foundation of our clinical trial and post-marketing businesses, which boast a top-tier scale and proven track record in Japan, we are actively engaging in data business and new ventures, constantly striving for evolution.
Divamics Inc
Divamics Inc. is a cross-disciplinary company with the core technology of AI and physics force field, helping collaborators to hunt new hits and PCCs in a more efficient and accurate way, especially for undrugable targets. Also, we offer clinical insights, such as resistance analyses and expansion of drug indications. Our signature capacities include drug design for GPCR, allosteric sites, and PPI, transcription factors. Our targeting modalities cover small molecules, peptides, PROTAC, XDC, synthetic biology, and more. We have already collaborated with 25+ MNCs/bioteches to advance over 35 new drug development pipelines and achieved multiple breakthrough results. Our records include: *FIC Project: Pioneering Drug Development* 1. Proposed binding site hypotheses, enabling the creation of drugs from scratch 2. Identified hits within 30 syntheses in a FIC pipeline with no pre-existing clinical drugs *BIC Project: Revolutionizing Structural Optimization* 1. Combined SAR computational analysis with expert medicinal chemistry insights to innovate structural optimization 2. Achieved patent breakthrough and better potency within just 6 syntheses of peptides, currently in Phase II clinical trials; Phase II clinical trial data to be presented at the ADA Conference, June 2024 We want to find collaborators such as the early discovery departments of MNCs, biopharmaceuticals and biotechs, with flexible cooperation modes including strategic joint research and others. | Divamics Inc. is a cross-disciplinary company with the core technology of AI and physics force field, helping collaborators to HUNT NEW LEADs and PCCs in a more efficient and accurate way, especially for UNDRUGGABLE targets. Also, we offer clinical insights, such as resistance analyses and expansion of drug indications. Currently, we have 40+ partners (10 listed companies/MNCs, 2 USA biotechs) for 60 pipeline projects, while 2 of them have reached end of Phase Ⅲ. We work on strategic collaboration mode, or offer AI+DBDD services, based on our partners’ needs. | Divamics: Redefining the Speed of Precision Medicine Divamics is an AI-driven biotech leader accelerating the journey from hit identification to preclinical candidate (Hits-to-PCC). By integrating advanced AI with molecular dynamics, we provide biopharma partners with the clarity and confidence to make critical discovery decisions faster. With a proven track record of supporting 80+ pipelines for over 50 global partners, we have successfully reduced PCC discovery timelines to just 0.5 – 1.5 years. Our platform delivers unmatched precision across four key modalities: small molecules, peptides, antibodies, and nucleic acids.
Coriolis Pharma Research GmbH
Coriolis Pharma is a global contract research organization and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs, including cell and gene therapy products and vaccines. The company’s offerings include liquid and lyophilized freeze-dried drug formulation development from early stage to market approval and beyond, lyophilization freeze-drying process development, and analytical development under R&D and GMP. Non-GMP manufacturing services for a wide range of products complete the service offering. More than 725 clients – from start-ups to big pharma – already rely on Coriolis’s scientific expertise. For each project, our highly skilled scientists develop customized study designs that align with our customers’ drug development strategies. | Coriolis Pharma is a globally operating contract research and development organization (CRDO) and a leader in formulation research and development of biopharmaceutical drugs, including cell and gene therapy products and vaccines. We provide high-quality services for liquid and lyophilized drug products from early stage to commercialization and beyond. Manufacturing support and contract analytical services under R&D and GMP complete our service portfolio. Coriolis was founded in 2008 and currently employs more than 200 employees from over 36 nations around the world. | Coriolis Pharma is a globally operating, science‑driven contract research and development organization (CRDO) specializing in drug product development, formulation, lyophilization technologies, and advanced analytics for biopharmaceuticals. Founded in 2008 and with laboraties in Europe and the U.S., the company supports clients from early development to commercialization, offering both R&D and GMP-compliant analytical services across a broad range of biological modalities. As a premier partner for biopharmaceutical innovation, Coriolis Pharma provides expertise in developing liquid and lyophilized drug products, optimizing stability for proteins, peptides, nucleic acids, vaccines, gene and cell therapy products, and virus(-like) particles up to biosafety level S2. Its interdisciplinary team, supported by an expert scientific advisory board, delivers cutting‑edge, tailor-made solutions designed to accelerate and de-risk drug development programs throughout the entire product lifecycle. Coriolis Pharma’s service portfolio includes comprehensive analytical method development, qualification, and validation, ensuring robust regulatory support for biopharmaceutical pipelines. Its commitment to scientific excellence, innovation, and independent operation makes the company a trusted partner for biotechnology firms and pharmaceutical developers worldwide. Meet Coriolis Pharma at the BIO Convention to learn how their integrated development, analytical, and manufacturing services can help advance your biotherapeutic programs faster, safer, and more efficiently.
COD Research USA Inc
COD Research is a leading CRO based in the US and India, specializing in global clinical trials and pharmacovigilance services. With a strong focus on biosimilar trials worldwide, we offer tailored solutions, ensuring quality, compliance, and client satisfaction. Our commitment is to contribute to the advancement of healthcare by delivering reliable and efficient services on an international scale. | We are a technical full-service Contract Research Organization (CRO) that offers end-to-end Clinical Trial Services, complemented by an industry-leading suite of specialized Pharmacovigilance Solutions. Our flexible working models are designed to seamlessly integrate with your teams, whether you require functional services for global studies or tailored on-site and off-site support. | We are a technical Full Service CRO that offers end-to-end Clinical Trial Services, complemented by an industry-leading suite of specialized Pharmacovigilance Solutions. Our flexible working models are designed to seamlessly adapt to client requirements, whether you require functional solutions or global studies or tailored on-site and off-site support.
CatSci
Spun out of AstraZeneca in 2010, CatSci is an award-winning innovation partner, dedicated to breaking down silos in drug development to accelerate the delivery of life-changing medicines. They proudly serve customers across the globe, delivering perfect-for-purpose solutions that balance timelines and resources with maximum flexibility. CatSci’s tailored services include route scouting and selection, initial scale-up and risk management for early development. For later development, they provide process design, assessment and optimisation, scale-up for clinical and commercial manufacture, tech transfer and post-approval improvements. They have specialist facilities in Process R&D, catalysis, high pressure reactions, crystallisation, pre-formulation, analytical development, HPAPI development and non-GMP material supply, and recently launched their oligonucleotides capability. Through their partnership with AGC Pharma Chemicals, they offer scalable small molecule API manufacturing, from grams to tonnes, with complete accountability of tech transfer. CatSci’s overall mission is to enable customers to create innovative therapeutics that will improve patient quality of life. They aim to become a ‘digital first, intelligent automation next’ business, freeing up the hands and minds of scientists through digital tools, enabling them to create perfect-for-purpose solutions that solve customers’ problems. Their purpose is and always will be to get medicines into the hands of patients in need. | CatSci Ltd is a UK-based award-winning innovation partner, dedicated to breaking down the silos in the development of small molecules, TACs and glues, and oligonucleotides to accelerate the delivery of life-changing medicines to patients in need. We proudly serve customers across the globe with projects, meeting their needs from candidate selection to product launch and beyond. Our tailored services include route scouting and selection, initial scale-up and risk management for early development. For later development, we provide process design, assessment and optimisation, scale-up for clinical and commercial manufacture, tech transfer and post-approval improvements. We possess a range of critical enabling technologies in research, development and manufacturing of small molecule and new modality therapeutics, with specialist facilities in chemical development, catalysis, material science, pre-formulation, HPAPI development, GMP analytical services, and oligonucleotide R&D and supply. Through our partnership with AGC Pharma Chemicals, we offer scalable small molecule GMP API material supply, from grams to tonnes, with seamless knowledge transfer. Agile, commercially minded and scientifically led, CatSci leverages its highly qualified technical team and state-of-the-art facilities to empower our customers to create affordable, best-in-class therapeutics in a safer, greener and more cost-effective way. Together, we can meet the evolving healthcare needs of the world. Recent recognition includes the 2023 UK Fast Growth 50 Index Award (Innovative Growth), the highly esteemed Queen’s Award for Enterprise: International Trade 2022, the 2022 Bionow Awards (Export of the Year), the 2022 Inspire Business Awards (Business of the Year (25+ employees)), the 2022 Wales Business Awards (Workplace Wellbeing), the 2022 Wales STEM Awards (STEM Company of the Year (50+ Employees) and STEM Ambassador of the Year), and the 2022 Cardiff Business Award (International Business of the Year). | CatSci Ltd is an award-winning innovation partner, dedicated to breaking down the silos in the CMC development of small molecules, TACS, glues, oligonucleotides and other complex medicines to accelerate the delivery of life-changing therapeutics to patients. We proudly serve customers across the globe with projects, meeting their needs from candidate selection to product launch and beyond. Our tailored services include route scouting and selection, initial scale-up and risk management for early development. For later development, we provide process design, assessment and optimisation, scale-up for clinical and commercial manufacture, tech transfer and post-approval improvements. We possess a range of critical enabling technologies in research, development and manufacturing of small molecule and new modality therapeutics, with specialist facilities in chemical development, catalysis, material science, pre-formulation, HPAPI development, GMP analytical services, and oligonucleotide R&D and supply. Through our partnership with AGC Pharma Chemicals, we offer scalable small molecule API manufacturing, from grams to tonnes, with complete accountability of tech transfer. Agile, commercially minded and scientifically led, CatSci leverages its highly qualified technical team and state-of-the-art facilities to empower our customers to create affordable, best-in-class therapeutics in a safer, greener and more cost-effective way. Together, we can meet the evolving healthcare needs of the world. Recent recognition includes the 2024 Finance Awards Wales (ESG Excellence), the 2023 UK Fast Growth 50 Index Award (Innovative Growth), the Queen’s Award for Enterprise: International Trade 2022, the 2022 Bionow Awards (Export of the Year), the 2022 Inspire Business Awards (Business of the Year (25+ employees)), the 2022 Wales Business Awards (Workplace Wellbeing), the 2022 Wales STEM Awards (STEM Company of the Year (50+ Employees), and the 2022 Cardiff Business Award (International Business of the Year). | Spun out of AstraZeneca in 2010, CatSci is an award-winning innovation partner, dedicated to breaking down silos in drug development to accelerate the delivery of life-changing medicines. They proudly serve customers across the globe, delivering perfect-for-purpose solutions that balance timelines and resources with maximum flexibility. CatSci’s tailored services include route scouting and selection, initial scale-up and risk management for early development. For later development, they provide process design, assessment and optimisation, scale-up for clinical and commercial manufacture, tech transfer and post-approval improvements. They have specialist facilities in Process R&D, catalysis, high pressure reactions, crystallisation, preformulation, analytical development, HPAPI development and oligonucleotide development, they recently launched their peptide and bioscience capability.
Avance Clinical
About Avance Clinical Avance Clinical is the largest premium full-service Australian and US CRO delivering quality clinical trials, with globally accepted data, in Australia, New Zealand and the US for international biotechs. The company’s clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services. Frost & Sullivan Awards Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past three years, has been providing CRO services in the region for more than two decades. Pre-clinical through to Phase 1 and 2 Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes. With experience across more than 110 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review. Technology Avance Clinical uses state-of-the-art technology and gold-standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, IBM Watson and Medrio are just some of the technology partners. www.avancecro.com | Avance Clinical is a full-service CRO for biotechs with a proven track-record for delivering clinical excellence in Australia, New Zealand, and North America. As the largest premium full-service CRO in Australia and North America, Avance Clinical specializes in delivering top-tier clinical trials that yield globally accepted data. Avance Clinical has been recognized for the fourth consecutive year by Frost & Sullivan in 2023, being awarded the Best Practices Customer Value Leadership for Biotech’s award, for its continuous exceptional performance. Avance Clinical offers pre-clinical consultancy services with their experienced ClinicReady team right through to Phase I and beyond clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes that are available in Australia and highly qualified sites and networks within the United States. With experience across more than 110 therapeutic indications, Avance Clinical can deliver world-class, high-quality, internationally accepted data suitable for FDA and EMA review. Avance Clinical uses state-of-the-art technology and gold-standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, Zelta, Veeva and Medrio are just some of Avance Clinical’s technology partners. www.avancecro.com | THE AUSTRALIA-BASED GLOBAL CRO FOR BIOTECHS Avance Clinical is a full-service Contract Research Organization (CRO) headquartered in Australia, with extensive operations across New Zealand, Asia, North America, and Europe. As the market leaders in Early Phase clinical trials, we leverage the unique advantages of the Australian market, including rapid ethics approval, no IND requirement, and the 43.5% R&D tax rebate, to provide biotechs with an accelerated pathway to clinical success. Specializing in world-class operations, we guide biotechs from early pre-clinical development through to late-phase studies. With a focus on agility, innovation, and cost-effectiveness, we deliver fast results backed by robust, globally accepted data. With expertise spanning over 250+ indications, across all therapeutic areas, over the last three decades, Avance Clinical consistently delivers data recognized by key global regulators, including the TGA, FDA, EMA, MHRA, MFDS, and PDMA. What sets us apart is our personalized service tailored to each client, ensuring customized, flexible solutions rather than a one-size-fits-all approach. | Avance Clinical is a leading, full-service Contract Research Organization (CRO) specialising exclusively in the delivery of high-quality clinical trial services for biopharmaceutical companies. With deep expertise across early- to late-phase clinical development, Avance Clinical partners with innovative biotech companies globally to accelerate the development of novel therapeutics. Founded in Australia, Avance Clinical is recognised for its strong scientific leadership, agile operating model, and consistent delivery of high-quality clinical trial data accepted by major global regulatory authorities, including the FDA and EMA. The company provides end-to-end clinical development services, including clinical operations, project management, regulatory affairs, biostatistics, data management, medical writing, pharmacovigilance, and biometrics, across a broad range of therapeutic areas. A key differentiator of Avance Clinical is its Centres of Excellence (CoEs) model, which embeds deep therapeutic and functional expertise across the organisation. These CoEs are designed to support complex clinical programs through specialised scientific leadership, proven operational execution, and consistent global quality standards. The Early Phase Centre of Excellence supports rapid transition from preclinical development into first-in-human and early clinical studies. Leveraging Australia’s favourable regulatory framework—where no IND is required and study start-up timelines can be as short as five to six weeks—this CoE provides integrated expertise in protocol design, regulatory strategy, clinical pharmacology, PK/PD, dose escalation, and early safety evaluation. Sponsors also benefit from Australia’s 43.5% R&D tax rebate on eligible clinical trial expenditure, delivering significant cost efficiencies while maintaining world-class quality. Avance Clinical’s Oncology Centre of Excellence delivers specialised support across solid tumours and hematological malignancies, with particular strength in early-phase oncology trials. This CoE brings together scientific leadership and operational expertise in complex study designs, including adaptive trials, biomarker-driven studies, and multi-regional oncology programs. The team works closely with leading investigators, specialist oncology sites, and key opinion leaders to ensure efficient study execution and high-quality, regulatory-ready data. The Central Nervous System (CNS) Centre of Excellence provides dedicated expertise across neurological and psychiatric indications. The CNS CoE supports trials requiring complex endpoint selection, specialised rating scales, and rigorous data quality oversight, with a strong focus on rater training, consistency, and patient safety. The team has experience across both early- and late-phase CNS programs, supporting sponsors through regulatory interactions and clinical execution. Avance Clinical’s Renal and Metabolic Centre of Excellence focuses on clinical development programs in kidney disease, metabolic disorders, and related systemic conditions. This CoE brings deep experience in managing trials with complex patient populations, comorbidities, and long-term endpoints. The team supports protocol design, patient recruitment strategies, biomarker integration, and global site engagement to ensure efficient delivery of renal and metabolic studies across regions. Complementing its therapeutic CoEs, Avance Clinical operates functional Centres of Excellence across Biostatistics, Data Management, Medical Writing, Pharmacovigilance, and Regulatory Affairs. These functional CoEs ensure consistency, quality oversight, and regulatory compliance across all programs, enabling scalable and efficient global trial delivery. Avance Clinical’s Australian operations provide a strategic advantage for early-phase and complex clinical trials, offering rapid start-up timelines, cost efficiencies, and access to highly experienced investigators and clinical sites. The company’s global footprint spans Australia, North America, Asia, and Europe, enabling seamless execution of regional and multi-regional clinical trials. North America represents Avance Clinical’s largest market outside Australia, supporting the majority of its biotech clients, while its Asia hub in Seoul, South Korea, provides access to Asia-Pacific patient populations and supports later-phase multi-regional development strategies. Led by an experienced executive and scientific leadership team with extensive backgrounds in drug discovery, clinical development, and regulatory strategy, Avance Clinical is recognised for its commitment to quality, transparency, and long-term partnerships. The company works as a true extension of its sponsors’ teams, delivering flexible, biotech-focused solutions tailored to the needs of emerging and mid-size biopharmaceutical companies. As a trusted CRO partner, Avance Clinical is dedicated to advancing innovative therapies from first-in-human through to late-stage development, helping biopharmaceutical companies bring new medicines to patients faster, more efficiently, and with confidence in the quality of their clinical data.